Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine.
- Author:
Fong Seng LIM
1
;
Htay-Htay HAN
;
Jeanne-Marie JACQUET
;
Hans L BOCK
Author Information
- Publication Type:Journal Article
- MeSH: Diphtheria; immunology; Diphtheria-Tetanus-Pertussis Vaccine; Female; Haemophilus Vaccines; Haemophilus influenzae; immunology; Hepatitis B; prevention & control; Hepatitis B Antibodies; blood; Hepatitis B Vaccines; administration & dosage; Humans; Immunization Schedule; Infant; Infant, Newborn; Male; Poliovirus Vaccine, Inactivated; Singapore; Tetanus; immunology; Vaccination; Vaccines, Combined; administration & dosage; Vaccines, Inactivated
- From:Annals of the Academy of Medicine, Singapore 2007;36(10):801-806
- CountrySingapore
- Language:English
-
Abstract:
INTRODUCTIONChildren in Singapore receive vaccination against hepatitis B virus (HBV) at 0, 1 and 5 or 6 months of age, and vaccination against pertussis, diphtheria, tetanus, and polio at 3, 4 and 5 months of age. Parents often choose to vaccinate with the combined acellular-pertussis-inactivated polio-Hib vaccine (DTPa-IPV/Hib). We investigated whether a combined hexavalent vaccine, DTPa-HBV-IPV/Hib, could replace the separate administration of DTPa-IPV/Hib and HBV for the final vaccination at 5 months of age (Trial DTPa-HBV-IPV-075).
MATERIALS AND METHODSIn an open study, 150 children were randomised to complete their vaccination schedule with DTPa-IPV/Hib + HBV or DTPa-HBV-IPV/Hib.
RESULTSOne month after the final vaccination, there was no difference between groups in seroprotection rates or antibody concentrations against HBV. Seroprotection rates against diphtheria, tetanus, Hib and polio, as well as vaccine response rates to pertussis antigens were also similar between groups. Local and general symptoms occurred at a similar rate after the third dose of either vaccine.
CONCLUSIONThe immunogenicity and reactogenicity of the hexavalent vaccine DTPa-HBV-IPV/Hib (Infanrix hexa, GSK) group is comparable to that of separately administered DTPa-IPV/Hib and HBV vaccines. Combined hexavalent vaccine, DTPa-HBV-IPV/Hib, could replace the separate administration of DTPa-IPV/Hib and HBV for vaccination at 5 months of age, thereby reducing the number of injections required.
